Welcome to our dedicated page for Algernon Health news (Ticker: AGNPF), a resource for investors and traders seeking the latest updates and insights on Algernon Health stock.
Algernon Health Inc. (AGNPF), formerly Algernon Pharmaceuticals Inc., generates news that reflects its transition from a purely clinical-stage pharmaceutical developer to a healthcare company focused on brain-specific PET neuroimaging clinics and neurological programs. Company announcements highlight its plans to build a network of specialized clinics in North America for the early-stage detection of Alzheimer’s disease and other brain disorders, as well as updates on its drug development and subsidiary activities.
Investors and observers following AGNPF news will see disclosures about neuroimaging initiatives, including equipment orders and financing agreements for U.S. FDA-cleared brain PET systems, partnerships with imaging technology providers, and franchise and licensing arrangements obtained through the acquisition of NoBrainer Imaging Centers, Inc. These items outline how Algernon intends to deploy dedicated clinics and expand access to brain PET imaging in selected Canadian and U.S. markets.
News releases also cover Algernon’s ongoing pharmaceutical and neuroscience programs. This includes updates from Algernon NeuroScience, the company’s private subsidiary advancing a proprietary DMT program for stroke and traumatic brain injury, as well as intellectual property milestones for its chronic kidney disease candidate NP-251 (Repirinast). Additional coverage may address capital markets activity such as private placements, preferred share structures, and regulatory steps related to planned financings.
For readers tracking AGNPF, the news stream provides context on how Algernon is combining diagnostic imaging, clinic development, and drug research. Regularly reviewing these updates can help users understand changes in the company’s strategic focus, progress on clinic rollouts, developments in its neurological pipeline, and the evolution of its capital structure.
Algernon Pharmaceuticals is pleased to announce its participation in the 9th American Cough Conference in June 2023, where it will present results from its Phase 2a Study of NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis and chronic cough. Ifenprodil, an NMDA receptor antagonist, could pioneer new treatment avenues for these conditions. Dr. Peter Dicpinigaitis noted the drug's promising potential as a first-in-class therapy. The conference, which focuses on cough research and management, occurs biennially, highlighting the significance of this presentation.
Algernon Pharmaceuticals reported enhanced results from its Phase 2a study of NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis (IPF) and chronic cough. The analysis revealed a 32.0% reduction in mean 24-hour cough counts after 4 weeks and a 39.5% reduction at 12 weeks. Similarly, awake cough counts dropped by 30.2% and 37.4% respectively. Dr. Jacky Smith lauded the results, emphasizing Ifenprodil's potential, especially in IPF patients where treatment has been challenging. CEO Christopher J. Moreau noted Ifenprodil's growing efficacy could mean greater results in chronic cough cases without IPF.
Algernon Pharmaceuticals has announced promising topline data from its Phase 2 proof of concept study of NP-120 (Ifenprodil) as a treatment for idiopathic pulmonary fibrosis (IPF) and chronic cough. The study showed 65% of patients achieved stable or improved forced vital capacity (FVC) compared to an expected placebo effect of 40% (p=0.0225). Additionally, 30% of subjects demonstrated a significant reduction in cough frequency. The company plans to file a pre-IND application for a Phase 2b study with the FDA, indicating a potential new treatment pathway for IPF patients.
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) announced progress in its chronic kidney disease (CKD) research program using Repirinast, previously an asthma drug. In pre-clinical tests, Repirinast significantly reduced kidney fibrosis by 50%. The company is also exploring its use for acute interstitial nephritis. Manufacturing is underway, with a toxicology study planned post-synthesis, followed by a Phase 1 study set for Q4 2022. The global CKD drug market is projected to reach $15.8 billion by 2024, reflecting a substantial opportunity for Algernon's research endeavors.
Algernon Pharmaceuticals (CSE: AGN, OTCQB: AGNPF) announced an update on its Phase 1 clinical study of AP-188 (DMT), a psychedelic compound. The Company is finalizing the intravenous formulation needed for the study, set to begin in September 2022, with the Centre for Human Drug Research in the Netherlands. This trial aims to evaluate the safety, tolerability, and pharmacokinetics of DMT through prolonged infusion. The findings will inform future studies on DMT's potential in treating ischemic stroke and rehabilitation.
Algernon Pharmaceuticals has filed patent applications for novel salt forms of N,N-dimethyltryptamine (DMT), specifically nicotinate and pamoate, which may enhance DMT's efficacy and stability as a potential stroke treatment. Binding studies show these salts have similar receptor interactions compared to the traditional fumarate form. Additionally, pamoate exhibited neuroprotective effects in mouse models, and nicotinate showed improvements in neuroplasticity markers in rats. The company aims to solidify its intellectual property position around DMT as part of its drug repurposing strategy.
Algernon Pharmaceuticals has received a patent from the Canadian Intellectual Property Office for its treatment of interstitial lung disease using NP-120 (Ifenprodil), valid until 2038. The patent covers compositions and methods for treating idiopathic pulmonary fibrosis (IPF). Algernon is also pursuing active patent applications for Ifenprodil in the U.S., Europe, China, and Japan. The company is conducting a Phase 2 human trial for Ifenprodil's safety and efficacy in IPF patients, with topline data expected in July 2022.
Algernon Pharmaceuticals announced that patients in its Phase 2 study of NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis and chronic cough in Australia and New Zealand have requested ongoing access to the drug beyond the study period. The company is assisting these clinical sites in obtaining additional supplies via the Australian Government's Special Access Scheme. Topline data from the study is expected in July 2022. However, Algernon clarifies that it does not claim Ifenprodil can cure or treat these conditions at this time.
Algernon Pharmaceuticals Inc. has announced the database lock for its Phase 2 proof-of-concept study of NP-120 (Ifenprodil) targeting idiopathic pulmonary fibrosis (IPF) and chronic cough. The trial, which began in 2020 and enrolled 20 patients, aims to assess Ifenprodil's safety and efficacy. Topline data is expected in July 2022, with primary endpoints focusing on lung function and cough reduction. The study includes subgroup analysis based on cough counts and serum biomarkers of fibrosis.
Algernon Pharmaceuticals has announced the completion of patient treatment in its Phase 2 proof-of-concept study of NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis (IPF) and chronic cough. Topline data is expected in July 2022. The trial enrolled 20 patients to assess Ifenprodil's safety and efficacy, focusing on lung function and cough reduction. The company aims to provide insights into the drug’s unique mechanism against current treatments, highlighting a pressing need for new options in managing IPF, which has a high mortality rate within 3-4 years.
FAQ
What is the current stock price of Algernon Health (AGNPF)?
What is the market cap of Algernon Health (AGNPF)?
